Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Psychiatry/Borderline Personality Disorder

Borderline Personality Disorder

10

Pipeline Programs↗

15

Active Trials↗

11

Companies Involved↗

Borderline personality disorder is an early-stage landscape with 10 programs across 11 companies.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

25/100

Mech. Concentration

20/100

Completion Rate

79/100

Attrition Rate

11/100

Pipeline

Programs by Phase

Preclinical9

Guanfacine

Promius Pharma, LLC

Divalproex Sodium

Teva

Fludrocortisone

Jazz Pharmaceuticals

Oxytocin

Retrophin

Psychopharmaceuticals

Francisco Miguel Correia Sampaio

Phase 1

No programs

Phase 21

Ketamine Hydrochloride

Boehringer Ingelheim

Phase 3

No programs

Approved

No programs

Analysis

Trial Status

53

clinical trials

Completed26 · 49%

Recruiting9 · 17%

Unknown status5 · 9%

Terminated4 · 8%

Active, not recruiting3 · 6%

Not yet recruiting3 · 6%

Other3 · 6%

Clinical Trials

Trial Activity

53 trials

Cognitive Reappraisal Training Targeting Emotion Circuits As a Therapeutic Intervention in Borderline Patients

Recruiting·IIcahn School of Medicine at Mount Sinai·Preclinical·NCT06772831·130 enrolled

A Multi-center, Patient-blinded and Investigator-blinded, Randomized, Parallel-group, Superiority Study to Compare the Efficacy of Four Sessions of Amygdala fMRI-BOLD Neurofeedback With Yoked Sham-control Neurofeedback in the Treatment of Dysregulated Affect in Borderline Personality Disorder

Recruiting·CCentral Institute of Mental Health, Mannheim·Preclinical·NCT06626789·164 enrolled

CLINICAL TRIAL: Treatment of Borderline Personality Disorder by Targeting Ventrolateral Prefrontal-amygdala Circuit With Network-based Neuronavigated Transcranial Magnetic Stimulation

Recruiting·UUniversity of California, Los Angeles·Preclinical·NCT07197502·30 enrolled

A Pilot Trial of One Day Accelerated Intermittent Theta-burst Stimulation Plus D-cycloserine in Suicidal Patients With Borderline Personality Disorder (ONE-D BPD)

Recruiting·MMclean Hospital·Preclinical·NCT07460947·20 enrolled

Combining Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder: A Phase II Randomized, Midazolam-Controlled Clinical Trial (KET-DBT)

Recruiting·—·Phase 2·NCT07569198·120 enrolled

Affect-based Impulsivity in Borderline Personality Disorder: Developing a Neurocomputational Phenotype

Recruiting·UUniversity of North Carolina, Chapel Hill·Preclinical·NCT06880640·106 enrolled

Conceptualizing Borderline Personality Disorder as a Relationship Use Disorder

Recruiting·UUniversity Hospital, Montpellier·Preclinical·NCT07337889·194 enrolled

A Novel Drug for Borderline Personality Disorder

Recruiting·—·Phase 2·NCT02097706·150 enrolled

MDMA in Borderline Personality Disorder

Recruiting·YYale University·Phase 2·NCT06683014·10 enrolled

Effects of Psychiatric Admissions on Self-harm and Suicide in People With Borderline Personality Disorder

Active, not recruiting·LLund University·N/A·NCT06424509·390 enrolled

A Pilot Randomized Controlled Trial Evaluating an Alliance-Focused Dialectical Behaviour Therapy Training Intervention for Borderline Personality Disorder

Active, not recruiting·York University·Preclinical·NCT07119541·80 enrolled

Emotional Regulation and Impulsivity Among Adolescents with Borderline Personality Disorder

Active, not recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT03209102·66 enrolled

Combining Transcranial Magnetic Stimulation With Emotion Regulation Skills Training in Borderline Personality Disorder

Not yet recruiting·MMassachusetts General Hospital·Preclinical·NCT07714005·12 enrolled

The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder

Not yet recruiting·TTanta University·Phase 1·NCT06759298·60 enrolled

Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder

Not yet recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT07099534·38 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)